CRISPR Therapeutics AG

NasdaqGM:CRSP Lagerbericht

Marktkapitalisierung: US$4.7b

CRISPR Therapeutics Management

Management Kriterienprüfungen 4/4

CRISPR Therapeutics CEO ist Sam Kulkarni , ernannt in Dec 2017, hat eine Amtszeit von 8.42 Jahren. Die jährliche Gesamtvergütung beträgt $7.68M , bestehend aus 10% Gehalt und 90% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.26% der Aktien des Unternehmens, im Wert von $12.40M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.6 Jahre bzw. 6.9 Jahre.

Wichtige Informationen

Sam Kulkarni

Geschäftsführender

US$7.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts10.01%
Amtszeit als Geschäftsführer8.4yrs
Eigentum des Geschäftsführers0.3%
Durchschnittliche Amtszeit des Managements6.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.9yrs

Jüngste Management Updates

Analyseartikel • May 23

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Key Insights CRISPR Therapeutics' Annual General Meeting to take place on 30th of May Total pay for CEO Sam Kulkarni...

Recent updates

Seeking Alpha • 16h

These Are The Upcoming Catalysts For Crispr Therapeutics Stock

Summary Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026. Strong balance sheet with $1.65B net cash and disciplined R&D spending provides a 5–6 year runway, minimizing near-term CRSP dilution or capital risk. Read the full article on Seeking Alpha
Analyseartikel • Mar 27

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Mar 14

CRISPR Therapeutics: An Uninspiring Start For Casgevy

Summary CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from Casgevy yet, but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy adoption and stiff competition in CAR-T therapies, with no exciting pipeline developments. CRISPR remains a cautious "Hold" within a barbell portfolio, pending momentum from Casgevy's launch and clinical trial success outside rare diseases. Read the full article on Seeking Alpha
Seeking Alpha • Feb 13

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Summary Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth. With major data readouts expected in 2025 and potential Casgevy revenues, CRSP stock remains a compelling investment despite current share price stasis. Read the full article on Seeking Alpha
Seeking Alpha • Jan 16

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Summary CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT program and significant layoffs highlight its precarious position compared to CRISPR's better financial health and strategic advantages. CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Read the full article on Seeking Alpha
Analyseartikel • Dec 31

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up

CRISPR Therapeutics AG's ( NASDAQ:CRSP ) price-to-sales (or "P/S") ratio of 16.3x might make it look like a strong sell...
Seeking Alpha • Dec 29

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Summary Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024. Despite a slow roll-out, Casgevy's increasing patient demand, reimbursement agreements, and positive long-term efficacy data support a bright revenue outlook and potential profitability by 2028. Crispr's robust pipeline, including CTX310 and CTX320 for cardiovascular diseases, holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects. With $1.9 billion in cash, Crispr has financial stability for at least 3.6 years, supporting ongoing development without needing to raise capital, making it a "buy" for high-risk tolerant investors. Read the full article on Seeking Alpha
Analyseartikel • Dec 03

Here's Why We're Not Too Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Nov 11

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Summary CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals. With nearly $2bn in cash and a promising pipeline, CRISPR Therapeutics remains a compelling long-term investment - I'm anticipating significant developments by 2025. Read the full article on Seeking Alpha
Analyseartikel • Nov 07

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

It's been a good week for CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders, because the company has just released...
Seeking Alpha • Oct 28

Crispr Therapeutics: Poised For A Major Turnaround

Summary Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline. Despite competition, Crispr's first-mover advantage, strategic partnerships, and robust pipeline create a durable moat, making it a compelling investment in the biotech sector. Read the full article on Seeking Alpha
Analyseartikel • Oct 02

CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 20x CRISPR Therapeutics AG ( NASDAQ:CRSP ) may be sending very bearish...
Seeking Alpha • Sep 13

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Summary Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. CRSP remains highly shorted, with 20% of shares outstanding sold short. Considering Crispr's secular growth in the long term, perhaps short sellers are betting on near-term negative catalysts. Vertex is exploring an alternative to using Busulfan, which is used to clear out existing patient stem cells; finding a less toxic agent could increase Casgevy's patient population to 150k. Read the full article on Seeking Alpha
Analyseartikel • Sep 04

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 14

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Summary CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns. CRISPR's partnership with Vertex Pharmaceuticals mitigates some operational risks associated with gene therapy. Given the uncertainties, CRISPR Therapeutics stock remains a "hold" until clearer commercial success is evident. Read the full article on Seeking Alpha
Analyseartikel • Aug 09

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$46.96 Current...
Seeking Alpha • Aug 07

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Summary Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future. Crispr made a net loss of $126.4m in Q2, but retains ~$1.7bn of cash, and its pipeline contains assets potentially approvable near term, plus two in-vivo programs offering breakthrough treatments. In my view, Crispr Therapeutics is remains a highly attractive company to invest in with a clear path to >41bn in annual revenues. Read the full article on Seeking Alpha
Seeking Alpha • Jul 13

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Summary CRSP has achieved the highly coveted regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia. However, with revenue recognition only likely from Q4'24 or Q1'25 onwards, readers may want to temper their near-term expectations. At the same time, CRSP does not own the patent of its gene editing technology, with a patent battle still occurring between the two groups of inventors. As the stock continues to trade sideways since November 2021, we believe that its intermediate-term investment thesis is likely tied to its swing trade potential. CRSP is likely to remain volatile as well, attributed to the elevated short interest and intense insider selling, with it only suitable for investors with higher risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Jul 07

Crispr Therapeutics: Beaten Down But Not Broken

Summary CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program. CRSP aims to expand its TAM and reach sustainable profitability over time. I argue why CRSP is close to an inflection point, suggesting buyers should consider capitalizing on its recent pessimism. Read the full article on Seeking Alpha
Analyseartikel • Jun 18

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 19.3x CRISPR Therapeutics AG ( NASDAQ:CRSP ) is a stock to...
Seeking Alpha • Jun 10

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Summary CRISPR Therapeutics’ new gene-editing protocol gives it a legitimate claim to be the future of medicine. That powered the stock back in 2020-21. But at some point, it’ll take revenues and profits, not futurism to justify stock ownership. The in-progress launch of Casgevy, a gene-editing treatment for Sickle Cell Disease suggests that transition is closing in. But that’s still getting off the ground, making numbers hard to project, and leaving room for disappointments. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Summary CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the establishment of authorized treatment centers, and CRISPR has already set up more than 25 globally. Despite Q1 revenue missing estimates, the company is controlling expenses and shows a healthy balance sheet with a solid cash runway. The commercial success of Casgevy hinges on long-term patient outcomes and will likely face limited early adoption. Updated investment recommendation: change from "sell" to "hold" due to recent stock valuation adjustments and prudent expense management. Read the full article on Seeking Alpha
Analyseartikel • May 23

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Key Insights CRISPR Therapeutics' Annual General Meeting to take place on 30th of May Total pay for CEO Sam Kulkarni...
Analyseartikel • May 13

Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

Today is shaping up negative for CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders, with the analysts delivering a...
Analyseartikel • May 10

We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • May 09

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Transfusion Dependent Beta Thalassemia in the U.S., EU, and other territories, with the potential to "functionally cure" patients. Crispr Therapeutics has a strong balance sheet, a diverse pipeline, and the potential to expand its reach to a larger patient population in the future. Its three targets ex-Casgevy are Type 1 diabetes, immuno-oncology, and in-vivo gene therapy - some compelling progress is being made in each field. In short - what's not to like? One day, Crispr Therapeutics will get the valuation upgrade it deserves. Read the full article on Seeking Alpha
Seeking Alpha • May 03

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

Summary Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile. Crispr Therapeutics stock is also no longer overvalued, as late buyers likely rushed out quickly. The stock's selling intensify has also slowed, allowing dip-buyers an attractive opportunity to load up. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Crispr Therapeutics: Now Is The Time To Buy

Summary Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at least 24 months. Read the full article on Seeking Alpha
Analyseartikel • Apr 16

Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Insights The projected fair value for CRISPR Therapeutics is US$68.64 based on 2 Stage Free Cash Flow to Equity...
Seeking Alpha • Mar 26

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Summary Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insurers are showing interest in covering CASGEVY, providing further support for its commercial launch. Read the full article on Seeking Alpha
Analyseartikel • Feb 22

There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders would be excited to see that the share price has had a great month...
Seeking Alpha • Feb 22

Crispr Therapeutics: Cautiously Optimistic

Summary CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR-based therapy for sickle cell disease and beta-thalassemia and has a diverse pipeline targeting various diseases. Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Feb 01

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Summary Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia. In this article I'll look at Casgevy's market potential and its commercialisation challenges. The cost of Casgevy, treatment cons, scalability and accessibility pose serious challenges for widespread adoption. Which may justify the high short interest in the stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Crispr Therapeutics: Commercial Validation Is The Next Step

Summary CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible through an in-vivo solution. The concerns surrounding commercial launch risks are overshadowed by the potential of CRISPR Therapeutics. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Summary CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG and Vertex specifically designed for the treatment of sickle cell disease. Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as the first FDA-approved therapy utilizing CRISPR/Cas9. CASGEVY’s approach involves modifying the patient’s own hematopoietic (blood) stem cells using CRISPR/Cas9 technology. Read the full article on Seeking Alpha
Analyseartikel • Dec 25

CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

You may think that with a price-to-sales (or "P/S") ratio of 29.7x CRISPR Therapeutics AG ( NASDAQ:CRSP ) is a stock to...
Analyseartikel • Nov 02

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Oct 05

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$44.37 Current...
Analyseartikel • Sep 14

CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

With a price-to-sales (or "P/S") ratio of 23x CRISPR Therapeutics AG ( NASDAQ:CRSP ) may be sending very bearish...
Analyseartikel • Jul 24

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Jun 28

Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Insights CRISPR Therapeutics' estimated fair value is US$64.57 based on 2 Stage Free Cash Flow to Equity Current...
Analyseartikel • Apr 02

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Mar 06

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$68.38 CRISPR...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sam Kulkarni im Vergleich zu den Einnahmen von CRISPR Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

-US$569m

Dec 31 2025US$8mUS$769k

-US$582m

Sep 30 2025n/an/a

-US$488m

Jun 30 2025n/an/a

-US$468m

Mar 31 2025n/an/a

-US$386m

Dec 31 2024US$33mUS$746k

-US$366m

Sep 30 2024n/an/a

-US$240m

Jun 30 2024n/an/a

-US$266m

Mar 31 2024n/an/a

-US$217m

Dec 31 2023US$12mUS$725k

-US$154m

Sep 30 2023n/an/a

-US$354m

Jun 30 2023n/an/a

-US$416m

Mar 31 2023n/an/a

-US$524m

Dec 31 2022US$21mUS$700k

-US$650m

Sep 30 2022n/an/a

-US$681m

Jun 30 2022n/an/a

-US$633m

Mar 31 2022n/an/a

US$312m

Dec 31 2021US$17mUS$670k

US$378m

Sep 30 2021n/an/a

US$412m

Jun 30 2021n/an/a

US$447m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$9mUS$625k

-US$349m

Sep 30 2020n/an/a

-US$211m

Jun 30 2020n/an/a

US$20m

Mar 31 2020n/an/a

US$46m

Dec 31 2019US$16mUS$550k

US$67m

Vergütung im Vergleich zum Markt: SamDie Gesamtvergütung ($USD7.68M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD7.03M).

Entschädigung vs. Einkommen: SamDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Sam Kulkarni (47 yo)

8.4yrs
Amtszeit
US$7,678,477
Vergütung

Dr. Samarth Kulkarni also known as Sam, Ph D, serves as the Chief Executive Officer & Chairman of the Board of CRISPR Therapeutics AG since December 1, 2017. He has been an Independent Director of Repare T...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Samarth Kulkarni
CEO & Chairman8.4yrsUS$7.68m0.26%
$ 12.4m
Raju Prasad
Chief Financial Officer3.2yrsUS$3.59m0.016%
$ 755.8k
James Kasinger
General Counsel & Secretary9yrsUS$2.86m0.098%
$ 4.6m
Naimish Patel
Chief Medical Officer2yrsUS$4.31m0.014%
$ 638.2k
Shaun Foy
Co-Founderno datakeine Datenkeine Daten
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datakeine Datenkeine Daten
Craig Mello
Scientific Founder & Advisory Board Memberno datakeine Datenkeine Daten
Chad Cowan
Scientific Founderno datakeine Datenkeine Daten
Matthew Porteus
Scientific Founder & Advisory Board Memberno datakeine Datenkeine Daten
Daniel Anderson
Scientific Founder & Advisory Board Memberno datakeine Datenkeine Daten
Stephen Kennedy
Head of Technical Operations6.6yrskeine Datenkeine Daten
Susan Kim
Vice President of Corporate Communications & Investor Relationsno datakeine Datenkeine Daten
6.6yrs
Durchschnittliche Betriebszugehörigkeit
53yo
Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von CRSP ist erfahren und erfahren (durchschnittliche Amtszeit von 6.6 Jahren).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Samarth Kulkarni
CEO & Chairman7.9yrsUS$7.68m0.26%
$ 12.4m
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datakeine Datenkeine Daten
Craig Mello
Scientific Founder & Advisory Board Memberno datakeine Datenkeine Daten
Matthew Porteus
Scientific Founder & Advisory Board Memberno datakeine Datenkeine Daten
Daniel Anderson
Scientific Founder & Advisory Board Memberno datakeine Datenkeine Daten
Douglas Treco
Lead Independent Director5.9yrsUS$370.74k0.023%
$ 1.1m
Katherine High
Independent Director6.9yrsUS$358.12k0%
$ 0
Briggs Duncan W. Morrison
Independent Directorless than a yearUS$341.07k0.0054%
$ 252.9k
Simeon George
Independent Director11.1yrsUS$342.17k0%
$ 0
Stephen Elledge
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
John Greene
Independent Director6.9yrsUS$363.92k0.0073%
$ 340.0k
Ali Behbahani
Independent Director11.1yrsUS$348.24k0.00027%
$ 12.6k
6.9yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter

Erfahrener Vorstand: CRSPDie Vorstandsmitglieder gelten als erfahren (6.9 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/21 12:38
Aktienkurs zum Tagesende2026/05/21 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

CRISPR Therapeutics AG wird von 40 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jack AllenBaird
William PickeringBernstein
Alec StranahanBofA Global Research